Most Favored Nation Drug Pricing in the U.S.: Comparing GENEROUS, GLOBE and GUARD

The Trump administration has introduced three most-favored-nation (MFN) drug pricing initiatives designed to link U.S. pharmaceutical costs to prices paid in economically comparable countries. Most-favored-nation pricing requires manufacturers to provide rebates when U.S. prices exceed those in reference nations—a direct response to the persistent gap between U.S. drug prices and those in other developed economies.…

Quantifying the Impact of Medicaid Expansion

How did Medicaid expansion under the Affordable Care Act impact health insurance coverage, cost and mental health? That is the question asked by Andreyeva, Rochford and Marthey (2025). They use 2011-2019 data from the Behavioral Risk Factor Surveillance System (BRFSS) to examine outcomes for Americans aged 26–54 with at least one child living in the…

What will be DOGE’s impact on CMS?

In a statement today, CMS confirmed that Elon Musk and the Department of Government Efficiency (DOGE) has been given access to CMS payment systems: CMS has two senior Agency veterans – one focused on policy and one focused on operations – who are leading the collaboration with DOGE, including ensuring appropriate access to CMS systems…

Why don’t physicians accept Medicaid patients?

One reason is that reimbursement rates for Medicaid are lower than for Medicare or commercial insurance. Another (often overlooked) factor, however, is physician’s risk of payment denials and the administrative hassle they face trying to get reimbursed by Medicaid. A paper by Dunn et al. (2024)–cleverly named “A Denial a Day Keeps the Doctor Away“–shows…

Did President Biden backtrack on his pledge for increased public access to Medicare data?

The Biden Administration promised more access to Medicare data. Then the reverse happened. ProPublica explains: In January, the Biden administration pledged to increase public access to a wide array of Medicare information to improve health care for America’s most sick and vulnerable. Some Medicare plans’ lack of transparency “deprives researchers and doctors of critical data…

CMS and outcomes-based pricing for cell and gene therapy

New cell and gene therapies offer the promise of revolutionizing care for patients with genetic diseases. Many of these diseases impact kids and about a third of children in the US are insured by Medicaid or the Children’s Health Insurance Program (CHIP). The government faces a challenge: cell and gene therapies are potential breakthrough therapies…